{'fraction_non_alphanumeric': 0.01969057665260197, 'fraction_numerical': 0.0014064697609001407, 'mean_word_length': 5.980392156862745, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tying it all Together

Insulin therapy is associated with the most substantial A1C reductions of any diabetes treatment available. New insulin analogues and alternate delivery methods offer improved safety, efficacy, convenience, predictability, and greater ease of administration. Furthermore, recent evidence indicates that early, intensive insulin therapy may contribute to β-cell rest and provide a cardioprotective benefit. Patients and practitioners, however, often remain hesitant to initiate insulin treatment. This article will discuss frequently encountered barriers to insulin use and suggest strategies that can be incorporated at various time points to facilitate the transition to insulin therapy.